USA — Becton, Dickinson and Company (BD and Co.) has launched a new instrument for single-cell multiomics analysis that will allow scientists to conduct high-throughput studies without compromising sample integrity.

The platform will potentially accelerate time to discovery across a wide range of disciplines including immunology, genetic disease research, cancer, and chronic disease research.

The BD Rhapsody HT Xpress System allows scientists to isolate, barcode, and analyze single cells at high sample throughput — up to eight times more cells than previous BD single-cell analyzer models.

The system eliminates sample loss and allows scientists to analyze multiple samples and cell sizes and types, such as stem cells or cancer cells, at the same time, allowing them to gain more insights in less time.

The new technology will be on display at the Advances in Genome Biology and Technology (AGBT) General Meeting in Hollywood, Florida, from February 6 to 9.

Single-cell multiomics is a rapidly growing approach that allows researchers to examine multiple layers of “omics” (including genomics, transcriptomics, proteomics, and metabolomics) information on a single cell, allowing them to investigate more parameters and gain a more comprehensive understanding of health and disease.

BD will also unveil the BD Rhapsody Mouse TCR/BCR Multiomic Assay, a cell receptor profiling tool for single-cell studies, as well as the BD Flex Single-Cell Multiplexing Kits, a companion tool for single-cell studies on any BD Rhapsody system, allowing more elements to be measured in a single run by increasing the number of sample tags.

BD is nearing the end of early-access testing for the BD Rhapsody HT Xpress System, which will be commercially available worldwide soon.

Meanwhile, Becton, Dickinson and Company (BD) recently launched a new third-generation BD Kiestra Total Lab Automation System for microbiology laboratories.

The robotic track system is suitable for use with the BD Kiestra microbiology laboratory solution, which automates lab specimen processing.

In another recent development, BD and Certest Biotec received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for their molecular assay to detect the Mpox virus.

Previously, the company announced the U.S. launch of a urine culture application for use with its Kiestra lab automation incubation and imaging system.

The urine culture application automatically organizes specimens into meaningful worklists driven by user-defined expert rules for critical criteria, such as high-risk patients or complex specimens.

The company concluded the spin-off of its Diabetes Care business into a separate company, dubbed Embecta, on 1 April 2022.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.